Contribution of serotonin (5-hydroxytryptamine;: 5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine:: Acute and chronic pharmacological analyses

被引:110
作者
Filip, M
Bubar, MJ
Cunningham, KA [1 ]
机构
[1] Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA
[2] Polish Acad Sci, Inst Pharmacol, Krakow, Poland
关键词
D O I
10.1124/jpet.104.068841
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The role of serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor subtypes (5-HT2A R, 5-HT2B R, and 5-HT2C R) in acute cocaine-evoked hyperactivity was compared with their contribution to the development and expression of locomotor sensitization upon repeated, intermittent treatment with cocaine ( 10 mg/kg/day for 5 days) in male Wistar rats. Cocaine-evoked hyperactivity was significantly enhanced by pretreatment with the preferential 5-HT2A R agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and the 5-HT2C R antagonist SDZ SER-082 [(+)-cis-4,5,7a, 8,9,10,11,11a-octahydro-7H-10-methylindolo(1,7-BC)( 2,6) naphthyridine fumarate]. The 5-HT2A R antagonist SR 46349B [1(Z)-[2-(dimethylamino) ethoxyimino]- 1( 2- fluorophenyl)3-( 4-hydroxyphenyl)-2(E)-propene] and the preferential 5- HT2C R agonist MK 212 [6-chloro-2-(1-piperazinyl) pyrazine HCl] ( 2 mg/kg) significantly attenuated acute cocaine-evoked hyperactivity; however, a lower dose of MK 212 (0.3 mg/kg) enhanced cocaine-evoked hyperactivity. The 5-HT2BR agonist BW 723C86 (1-[5-(2-thienylmethoxy)-1H-3-indolyl] propan-2-amine HCl) and the 5-HT2B R antagonist SB 204741 [N-(1-methyl- 5-indolyl)- N'-(3-methyl-5-isothiazolyl) urea] had no effect on cocaine-evoked hyperactivity. Repeated treatment with cocaine alone resulted in a 2-fold increase in hyperactivity upon challenge with cocaine 5 days after termination of the cocaine regimen (sensitization). The 5-HT2A R antagonist SR 46349B also blocked cocaine-evoked hyperactivity following repeated cocaine treatment, whereas the other 5-HT2R ligands were ineffective. When any of the 5-HT2R ligands was coadministered with cocaine during the treatment regimen ( 10 mg/kg/day for 5 days), the development of sensitization was unchanged as measured by the level of cocaine-evoked hyperactivity upon challenge 5 days after termination of the treatment. The present study implies that 5-HT2AR and 5-HT2CR exert oppositional influence upon hyperactivity evoked by acute administration of cocaine; this balance is altered following repeated cocaine administration.
引用
收藏
页码:1246 / 1254
页数:9
相关论文
共 43 条
[1]   Alterations in serotonergic responsiveness during cocaine withdrawal in rats: Similarities to major depression in humans [J].
Baumann, MH ;
Rothman, RB .
BIOLOGICAL PSYCHIATRY, 1998, 44 (07) :578-591
[2]   5-HT2 RECEPTOR SUBTYPES - A FAMILY RE-UNITED [J].
BAXTER, G ;
KENNETT, G ;
BLANEY, F ;
BLACKBURN, T .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (03) :105-110
[3]   Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat:: An in vivo extracellular single cell study [J].
Blackburn, TP ;
Minabe, Y ;
Middlemiss, DN ;
Shirayama, Y ;
Hashimot, K ;
Ashby, CR .
SYNAPSE, 2002, 46 (03) :129-139
[4]   Selective serotonin reuptake inhibitors enhance cocaine-induced locomotor activity and dopamine release in the nucleus accumbens [J].
Bubar, MJ ;
McMahon, LR ;
De Deurwaerdère, P ;
Spampinato, U ;
Cunningham, KA .
NEUROPHARMACOLOGY, 2003, 44 (03) :342-353
[5]  
BUBAR MJ, 2003, 13616435 FASEB EXP B
[6]  
BUBAR MJ, 2002, DRUG ALCOHOL DEPEN, V61, pS22
[7]  
CALLAHAN PM, 1995, J PHARMACOL EXP THER, V274, P1414
[8]   Mediation of the discriminative stimulus properties of cocaine by mesocorticolimbic dopamine systems [J].
Callahan, PM ;
DelaGarza, R ;
Cunningham, KA .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 57 (03) :601-607
[9]   A region-specific increase in Gαq and Gα11 proteins in brains of rats during cocaine withdrawal [J].
Carrasco, GA ;
Zhang, YH ;
Damjanoska, KJ ;
D'Souza, DN ;
Garcia, F ;
Battaglia, G ;
Muma, NA ;
Van de Kar, LD .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (03) :1012-1019
[10]  
CUNNINGHAM KA, 1986, PSYCHOPHARMACOLOGY, V90, P193